



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 403/12, 401/12, A61K 31/435, 31/495</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/26210</p> <p>(43) International Publication Date: 11 May 2000 (11.05.00)</p>
<p>(21) International Application Number: PCT/US99/25041</p> <p>(22) International Filing Date: 26 October 1999 (26.10.99)</p> <p>(30) Priority Data: 60/106,294 30 October 1998 (30.10.98) US</p> <p>(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): SANDERSON, Philip, E. [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). LYLE, Terry [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). DORSEY, Bruce [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). STANTON, Matthew, G. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). NAYLOR-OLSEN, Adel, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).</p> <p>(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: THROMBIN INHIBITORS</p> <div style="text-align: center; margin: 20px 0;"> <p>(I)</p> </div> <div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;"> <p>(II)</p> </div> <div style="text-align: center;"> <p>(III)</p> </div> <div style="text-align: center;"> <p>(IV)</p> </div> </div> <div style="text-align: center; margin-top: 20px;"> <p>(V)</p> </div> <p>(57) Abstract</p> <p>Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having structure (I) or a pharmaceutically acceptable salt thereof, wherein b is NY¹ or O; c is CY² or N; d is CY²; e is CY¹ or N; f is CY¹ or N; g is CY¹ or N; Y¹ is hydrogen, C₁₋₄ alkyl, or halogen; Y² is hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, halogen, NH₂, OH or C₁₋₄ alkoxy; A is (II), (III), (IV) or (V); and W, X, Z, R³, R⁴ and R⁵ are defined in the specification.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION
THROMBIN INHIBITORS

BACKGROUND OF THE INVENTION

5 Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.

Edwards *et al.*, *J. Amer. Chem. Soc.*, (1992) vol. 114, pp. 1854-63,
10 describes peptidyl α -ketobenzoxazoles which are reversible inhibitors of the serine proteases human leukocyte elastase and porcine pancreatic elastase.

European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety.

15 Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or α -keto carboxyl derivatives.

R. J. Brown *et al.*, *J. Med. Chem.*, Vol. 37, pages 1259-1261 (1994) describes orally active, non-peptidic inhibitors of human leukocyte elastase which
20 contain trifluoromethylketone and pyridinone moieties.

H. Mack *et al.*, *J. Enzyme Inhibition*, Vol. 9, pages 73-86 (1995) describes rigid amidino-phenylalanine thrombin inhibitors which contain a pyridinone moiety as a central core structure.

25 SUMMARY OF THE INVENTION

The invention includes compounds for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
30 These compounds may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents. The compounds can be added to blood, blood products, or mammalian organs in order to effect the desired inhibitions.


The invention also includes a compound for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks,
35 atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis,

disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compounds may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.

- 5 The invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.

10 DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS



Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure:



- 15 or a pharmaceutically acceptable salt thereof, wherein b is NY^1 or O; c is CY^2 or N; d is CY^3 ; e is CY^4 or N; f is CY^5 or N; g is CY^6 or N; Y^4 , Y^5 , and Y^6 are independently hydrogen, C_{1-4} alkyl, or halogen; Y^1 , and Y^2 are independently hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, halogen, NH_2 , OH or C_{1-4} alkoxy, and Y^3 is hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, halogen, NH_2 , OH, CN or C_{1-4} alkoxy;

20

A is




or

W is

- 5 hydrogen,
 R^1 ,
 $R^1\text{OCO}$,
 $R^1\text{CO}$,
 $R^1\text{SO}_2$,
10 $R^1(\text{CH}_2)_n\text{NHCO}$, or
 $(R^1)_2\text{CH}(\text{CH}_2)_n\text{NHCO}$,
wherein n is 0-4;

 R^1 is

- 15 R^2 ,
 $R^2(\text{CH}_2)_m\text{C}(\text{R}^8)_2$, where m is 0-3, and each R^8 can be the same or different,
 $(\text{R}^2)(\text{OR}^2)\text{CH}(\text{CH}_2)_p$, where p is 1-4,



- 20 $R^2\text{C}(\text{R}^8)_2(\text{CH}_2)_m$, wherein m is 0-3, and each R^8 can be the same or different, wherein $(\text{R}^8)_2$ can also form a ring with C represented by C3-7 cycloalkyl,

- $R^2CH_2C(R^8)_2(CH_2)_q$, wherein q is 0-2, and each R^8 can be the same or different, wherein $(R^8)_2$ can also form a ring with C represented by C₃₋₇ cycloalkyl,
- 5 $(R^2)_2CH(CH_2)_r$, where r is 0-4 and each R^2 can be the same or different, and wherein $(R^2)_2$ can also form a ring with CH represented by C₃₋₇ cycloalkyl, C₇₋₁₂ bicyclic alkyl, C₁₀₋₁₆ tricyclic alkyl, or a 5- to 7-membered mono- or bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatoms selected from the group consisting of N, O and S,
- 10 $R^2O(CH_2)_p$, wherein p is 1-4,
 $R^2CF_2C(R^8)_2$,
 $(R^2CH_2)(R^2CH_2)CH$, or
 R^2SO_2 ,
 $R^2CH_2SO_2$,
- 15 $R^2(COOR^6)(CH_2)_r$, where r is 1-4;
- R^2 and R^5 are independently
hydrogen,
phenyl, unsubstituted or substituted with one or more of C₁₋₄
20 alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂, CH₂OH,
CO₂R⁷, where R⁷ is C₁₋₄ alkyl, or SO₂NH₂,
naphthyl,
biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
25 heterocyclic ring or non-heterocyclic ring which can be saturated or
unsaturated, wherein the heterocyclic ring contains from one to four
heteroatoms selected from the group consisting of N, O and S, and wherein
the heterocyclic or non-heterocyclic ring is unsubstituted or substituted with
halogen or hydroxy,
- 30 C₁₋₇ alkyl, unsubstituted or substituted with one or more of hydroxy,
COOH,
amino,
aryl,
C₃₋₇ cycloalkyl,

- CF₃,
N(CH₃)₂,
-C₁₋₃alkylaryl,
heteroaryl, or
heterocycloalkyl,
- 5 CF₃
C₃₋₇ cycloalkyl, unsubstituted or substituted with aryl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl;
- 10 R³, R⁴ and R⁶ are independently selected from the group consisting of
hydrogen,
halogen,
C₁₋₄ alkyl,
15 C₃₋₇ cycloalkyl,
trifluoromethyl,
CN,
SCH₃,
SOCH₃, or
20 SO₂CH₃;
- X is
hydrogen, or
halogen;
- 25 Z is CH₂, S, or SO₂;
- R⁸ is
hydrogen,
30 phenyl, unsubstituted or substituted with one or more of C₁₋₄
alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂,
halogen,
naphthyl,
biphenyl,

a 5- to 7- membered mono- or a 9- to 10-membered bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to four heteroatoms selected from the group consisting of N, O and S,

5 C₁₋₄ alkyl, unsubstituted or substituted with one or more of hydroxy,

COOH,

amino,

aryl,

heteroaryl, or

10 heterocycloalkyl,


CF₃

C₃₋₇ cycloalkyl,

C₇₋₁₂ bicyclic alkyl, or

C₁₀₋₁₆ tricyclic alkyl.

15 A class of compounds of the invention, or a pharmaceutically acceptable salt thereof, includes those wherein A is



wherein R³ is CH₃ or Cl.



20 A subclass of compounds of this class, or a pharmaceutically acceptable salt thereof, includes those wherein

Y¹, Y², Y³, Y⁴, Y⁵, and Y⁶ are independently hydrogen, C₁₋₄ alkyl, or NH₂; W is

R¹; R¹ is R²(CH₂)₂; and R² is a 5- to 7-membered mono- or a 9- to 10-membered

25 bicyclic heterocyclic ring or non-heterocyclic ring which can be saturated or unsaturated, wherein the heterocyclic ring contains from one to four heteroatoms selected from the group consisting of N, O, and S, and wherein the heterocyclic ring is unsubstituted.

In a group of compounds of this subclass, or a pharmaceutically acceptable salt thereof, Y^1 , Y^2 , Y^3 , Y^4 , Y^5 , and Y^6 are independently hydrogen, methyl or NH_2 ; and W is



5

In a subgroup of this group of compounds, b is NH, N(CH₃) or O, c is CH or N, d is CH, C(NH₂), e is CH, f is N or CH, and g is CH or N.

Examples of this group are listed below in Table 1. Inhibitory activity of compounds of the invention is represented by "***", indicating K_i greater than or equal to 100 nM, or "**", indicating K_i less than 100 nM. Values are as determined according to the in vitro assay described later in the specification.

10

Table 1












Table 1 (continued)



**



The compounds of the present invention, may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. The compounds of the present invention may also have polymorphic crystalline forms, with all polymorphic crystalline forms being included in the present invention.

When any variable occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy" represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "Halo", as used herein, means fluoro, chloro, bromo and iodo; and "counterion" is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate.

trifluoroacetate, perchlorate, nitrate, benzoate, maleate, sulfate, tartrate, hemitartrate, benzene sulfonate, and the like.

The term "C₃₋₇cycloalkyl" is intended to include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like.

5 The term "C₇₋₁₂ bicyclic alkyl" is intended to include bicyclo[2.2.1]heptyl (norbornyl), bicyclo[2.2.2]octyl, 1,1.3-trimethyl-bicyclo[2.2.1]heptyl (bornyl), and the like.

10 The term "aryl" as used herein except where noted, represents a stable 6- to 10-membered mono- or bicyclic ring system. The aryl ring can be unsubstituted or substituted with one or more of C₁₋₄ lower alkyl; hydroxy; alkoxy; halogen; amino. Examples of "aryl" groups include phenyl and naphthyl.

15 The term "heterocycle" or "heterocyclic ring", as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 9- to 10-membered bicyclic heterocyclic ring system any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. Bicyclic unsaturated ring systems
20 include bicyclic ring systems which may be partially unsaturated or fully unsaturated. Partially unsaturated bicyclic ring systems include, for example, cyclopentenopyridinyl, benzodioxan, methylenedioxyphenyl groups. Especially useful are rings containing one oxygen or sulfur, one to four nitrogen atoms, or one oxygen or sulfur combined with one or two nitrogen atoms. The heterocyclic ring
25 may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic groups include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiophenyl, oxazolyl,
30 thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, tetrazole, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone,

and oxadiazolyl. Morpholino is the same as morpholinyl. Unsaturated heterocyclic rings may also be referred to hereinafter as "heteroaryl" rings.

The pharmaceutically-acceptable salts of the compounds of Formula I (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts such as those derived from inorganic acids, e.g. hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases. Examples of acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

Some abbreviations that may appear in this application are as follows.

ABBREVIATIONS

<u>Designation</u>	<u>Protecting Group</u>
BOC (Boc)	t-butyloxycarbonyl
CBZ (Cbz)	benzyloxycarbonyl(carbobenzoxo)
TBS (TBDMS)	t-butyl-dimethylsilyl

Activating Group

HBT(HOBT or HOBt)

1-hydroxybenzotriazole hydrate

Designation

BOP reagent

Coupling Reagent

benzotriazol-1-yloxytris-

(dimethylamino)phosphonium

hexafluorophosphate

BOP-Cl

bis(2-oxo-3-oxazolidinyl)phosphinic chloric

EDC

1-ethyl-3-(3-dimethylaminopropyl)

carbodiimide hydrochloride

Other(BOC)₂O (BOC₂O)

di-t-butyl dicarbonate

n-Bu₄N⁺F⁻

tetrabutyl ammonium fluoride

nBuLi (n-Buli)

n-butyllithium

DMF

dimethylformamide

Et₃N (TEA)

triethylamine

EtOAc

ethyl acetate

TFA

trifluoroacetic acid

DMAP

dimethylaminopyridine

DME

dimethoxyethane

NMM

N-methylmorpholine

DPPA

diphenylphosphoryl azide

THF

tetrahydrofuran

DIPEA

diisopropylethylamine

Amino Acid

Ile

Isoleucine

Phe

Phenylalanine

Pro

Proline

Ala

Alanine

Val

Valine

5 In vitro assay for determining proteinase inhibition

Assays of human α -thrombin and human trypsin were performed by the methods substantially as described in *Thrombosis Research*, Issue No. 70, page 173 (1993) by S.D. Lewis *et al.*

The assays were carried out at 25°C in 0.05 M TRIS buffer pH 7.4.
5 0.15 M NaCl, 0.1% PEG. Trypsin assays also contained 1 mM CaCl_2 . In assays wherein rates of hydrolysis of a *p*-nitroanilide (pna) substrate were determined, a Thermomax 96-well plate reader was used to measure (at 405 nm) the time dependent appearance of *p*-nitroaniline. sar-PR-pna was used to assay human α -thrombin ($K_m=125 \mu\text{M}$) and bovine trypsin ($K_m=125 \mu\text{M}$). *p*-Nitroanilide substrate
10 concentration was determined from measurements of absorbance at 342 nm using an extinction coefficient of $8270 \text{ cm}^{-1}\text{M}^{-1}$.

In certain studies with potent inhibitors ($K_i < 10 \text{ nM}$) where the degree of inhibition of thrombin was high, a more sensitive activity assay was employed. In this assay the rate of thrombin catalyzed hydrolysis of the fluorogenic substrate Z-
15 GPR-afc ($K_m=27 \mu\text{M}$) was determined from the increase in fluorescence at 500 nm (excitation at 400 nm) associated with production of 7-amino-4-trifluoromethyl coumarin. Concentrations of stock solutions of Z-GPR-afc were determined from measurements of absorbance at 380 nm of the 7-amino-4-trifluoromethyl coumarin produced upon complete hydrolysis of an aliquot of the stock solution by thrombin.

20 Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration $\leq 0.1 K_m$ into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (V_o) or presence of inhibitor (V_i)
25 were measured. Assuming competitive inhibition, and that unity is negligible compared $K_m/[S]$, $[I]/e$, and $[I]/e$ (where $[S]$, $[I]$, and e respectively represent the total concentrations, of substrate, inhibitor and enzyme), the equilibrium constant (K_i) for dissociation of the inhibitor from the enzyme can be obtained from the dependence of V_o/V_i on $[I]$ shown in equation 1: $V_o/V_i = 1 + [I]/K_i$ (1).

30 The activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of

recanalized vessels. The compounds of the invention are selective compounds, as evidenced by their inhibitory activity against human trypsin (represented by Ki).

Thrombin Inhibitors - Therapeutic Uses- Method of Using

5 Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy. The term "patient" used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats,
10 rats, and mice.

 Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, the
15 thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.

20 Compounds of the invention are useful for treating or preventing venous thromboembolism (e.g. obstruction or occlusion of a vein by a detached thrombus; obstruction or occlusion of a lung artery by a detached thrombus), cardiogenic thromboembolism (e.g. obstruction or occlusion of the heart by a detached thrombus), arterial thrombosis (e.g. formation of a thrombus within an artery
25 that may cause infarction of tissue supplied by the artery), atherosclerosis (e.g. arteriosclerosis characterized by irregularly distributed lipid deposits) in mammals, and for lowering the propensity of devices that come into contact with blood to clot blood.

 Examples of venous thromboembolism which may be treated or
30 prevented with compounds of the invention include obstruction of a vein, obstruction of a lung artery (pulmonary embolism), deep vein thrombosis, thrombosis associated with cancer and cancer chemotherapy, thrombosis inherited with thrombophilic diseases such as Protein C deficiency, Protein S deficiency, antithrombin III deficiency, and Factor V Leiden, and thrombosis resulting from acquired
35 thrombophilic disorders such as systemic lupus erythematosus (inflammatory

connective tissue disease). Also with regard to venous thromboembolism, compounds of the invention are useful for maintaining patency of indwelling catheters.

5 Examples of cardiogenic thromboembolism which may be treated or prevented with compounds of the invention include thromboembolic stroke (detached thrombus causing neurological affliction related to impaired cerebral blood supply), cardiogenic thromboembolism associated with atrial fibrillation (rapid, irregular twitching of upper heart chamber muscular fibrils), cardiogenic thromboembolism associated with prosthetic heart valves such as mechanical heart valves, and cardiogenic thromboembolism associated with heart disease.

10 Examples of arterial thrombosis include unstable angina (severe constrictive pain in chest of coronary origin), myocardial infarction (heart muscle cell death resulting from insufficient blood supply), ischemic heart disease (local anemia due to obstruction (such as by arterial narrowing) of blood supply), reocclusion during or after percutaneous transluminal coronary angioplasty, restenosis after percutaneous
15 transluminal coronary angioplasty, occlusion of coronary artery bypass grafts, and occlusive cerebrovascular disease. Also with regard to arterial thrombosis, compounds of the invention are useful for maintaining patency in arteriovenous cannulas.

Examples of atherosclerosis include arteriosclerosis.

20 Examples of devices that come into contact with blood include vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems

The thrombin inhibitors of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed
25 release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent.
30 For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.

The thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be
35 compressed into pellets or small cylinders and implanted subcutaneously or

intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example. Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.

5 The thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

10 The thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the thrombin inhibitors may be coupled to a class of
15 biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.

20 The dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian
25 can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

Oral dosages of the thrombin inhibitors, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 30 mg/kg/day, preferably 0.025-7.5 mg/kg/day, more preferably 0.1-2.5
30 mg/kg/day, and most preferably 0.1-0.5 mg/kg/day (unless specified otherwise, amounts of active ingredients are on free base basis). For example, an 80 kg patient would receive between about 0.8 mg/day and 2.4 g/day, preferably 2-600 mg/day, more preferably 8-200 mg/day, and most preferably 8-40 mg/kg/day. A suitably prepared medicament for once a day administration would thus contain between 0.8
35 mg and 2.4 g, preferably between 2 mg and 600 mg, more preferably between 8 mg

and 200 mg, and most preferably 8 mg and 40 mg, e.g., 8 mg, 10 mg, 20 mg and 40 mg. Advantageously, the thrombin inhibitors may be administered in divided doses of two, three, or four times daily. For administration twice a day, a suitably prepared medicament would contain between 0.4 mg and 4 g, preferably between 1 mg and 300 mg, more preferably between 4 mg and 100 mg, and most preferably 4 mg and 20 mg, e.g., 4 mg, 5 mg, 10 mg and 20 mg.

Intravenously, the patient would receive the active ingredient in quantities sufficient to deliver between 0.025-7.5 mg/kg/day, preferably 0.1-2.5 mg/kg/day, and more preferably 0.1-0.5 mg/kg/day. Such quantities may be administered in a number of suitable ways, e.g. large volumes of low concentrations of active ingredient during one extended period of time or several times a day, low volumes of high concentrations of active ingredient during a short period of time, e.g. once a day. Typically, a conventional intravenous formulation may be prepared which contains a concentration of active ingredient of between about 0.01-1.0 mg/ml, e.g. 0.1 mg/ml, 0.3 mg/ml, and 0.6 mg/ml, and administered in amounts per day of between 0.01 ml/kg patient weight and 10.0 ml/kg patient weight, e.g. 0.1 ml/kg, 0.2 ml/kg, 0.5 ml/kg. In one example, an 80 kg patient, receiving 8 ml twice a day of an intravenous formulation having a concentration of active ingredient of 0.5 mg/ml, receives 8 mg of active ingredient per day. Glucuronic acid, L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration may be used as buffers. Consideration should be given to the solubility of the drug in choosing an The choice of appropriate buffer and pH of a formulation, depending on solubility of the drug to be administered, is readily made by a person having ordinary skill in the art.

The compounds can also be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regime.

The thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixers, syrups and the like, and consistent with convention pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.

Typical uncoated tablet cores suitable for administration of thrombin inhibitors are comprised of, but not limited to, the following amounts of standard ingredients:

Excipient	General Range (%)	Preferred Range (%)	Most Preferred Range (%)
mannitol	10-90	25-75	30-60
microcrystalline cellulose	10-90	25-75	30-60
magnesium stearate	0.1-5.0	0.1-2.5	0.5-1.5

Mannitol, microcrystalline cellulose and magnesium stearate may be substituted with alternative pharmaceutically acceptable excipients.

The thrombin inhibitors can also be co-administered with suitable anti-platelet agents, including, but not limited to, fibrinogen receptor antagonists (e.g. to treat or prevent unstable angina or to prevent reocclusion after angioplasty and restenosis), anticoagulants such as aspirin, thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various vascular pathologies, or lipid lowering agents including antihypercholesterolemics


(e.g. HMG CoA reductase inhibitors such as lovastatin, HMG CoA synthase inhibitors, etc.) to treat or prevent atherosclerosis. For example, patients suffering from coronary artery disease, and patients subjected to angioplasty procedures, would benefit from coadministration of fibrinogen receptor antagonists and thrombin inhibitors. Also, thrombin inhibitors enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion. Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter.

Typical doses of thrombin inhibitors of the invention in combination with other suitable anti-platelet agents, anticoagulation agents, or thrombolytic agents may be the same as those doses of thrombin inhibitors administered without coadministration of additional anti-platelet agents, anticoagulation agents, or thrombolytic agents, or may be substantially less than those doses of thrombin inhibitors administered without coadministration of additional anti-platelet agents, anticoagulation agents, or thrombolytic agents, depending on a patient's therapeutic needs.


General procedure for making compounds of the invention

Compounds may be prepared, for example, by a common condensation reaction between a group having a carboxylic acid moiety and a group having an amino moiety, forming a peptide or amide bond. Compounds may be prepared by other means however, and suggested starting materials and procedures described below are exemplary only and should not be construed as limiting the scope of the invention.


In general, compounds having the general structure



wherein the variables have the above-described meanings, can be prepared by reacting




Suitable carboxylic acid starting materials for






 may be prepared according to the following procedures.

Carboxylic acids

METHOD 1

- 5 Starting allylamine is condensed with acetaldehyde and cyanide in Step A to afford the aminonitrile. This is reacted in Step B with oxalyl chloride according to the method of Hoornaert [*J. Heterocyclic Chem.*, 20, 919, (1983)] to give the pyrazinone. The olefin is oxidatively cleaved with ruthenium tetroxide and the resulting aldehyde is converted to the acid by an oxidizing agent such as chromic acid
- 10 in Step C. The 3-chloro group is then displaced by an ammonia equivalent, in this case *p*-methoxybenzylamine in Step D. The remaining chlorine is removed by reduction with Raney nickel in Step E and in Step F the *p*-methoxybenzyl group is removed by treatment with a strong acid such as TFA.





Typically, solution phase amide couplings may be used to form the
5 final product, but solid-phase synthesis by classical Merrifield techniques may be
employed instead. The addition and removal of one or more protecting groups is also
typical practice.

Modifications of the method will allow different W, R³, X and A
groups contemplated by the scope of the broad claim below to be present by the use of
10 an appropriate reagent or appropriately substituted starting material in the indicated

synthetic step. For example the starting aldehyde in Step A can have as its side chain, ethyl, isopropyl, cyclopropyl, trifluoromethyl, and the like, to achieve the different operable values of R^3 . Likewise, different W groups can be present by the use of an appropriate amine in Step D. Different X groups can be present by the omission of
5 step E, and by the use of a reagent such as oxalyl bromide in step B. Obvious variations and modifications of the method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.





METHOD 2

10 The acid from METHOD 1, Step C is coupled to the appropriate amine. The 3-chloro group is then displaced by the appropriate amine and a protecting group is then removed, if necessary, to give the final product.

Modifications of the method will allow different W, R^3 , and X groups contemplated by the scope of the broad claim below to be present by the use of an
15 appropriate reagent or appropriately substituted starting material in the indicated synthetic step. Obvious variations and modifications of the method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.

METHOD 3


20 An ester of glycine, in this case the benzyl ester, is condensed with acetaldehyde and cyanide in Step A to afford the aminonitrile. This is reacted in Step B with oxalyl chloride to give the pyrazinone. The 3-chloro group is then displaced by the appropriate amine, in this case phenethylamine, in Step C. The ester is hydrolyzed in Step D and the remaining chlorine is then removed by hydrogenolysis
25 in Step E.



METHOD 4

- 5 Starting allylamine is condensed with acetaldehyde and cyanide in Step A to afford the aminonitrile. This is reacted in Step B with oxalyl chloride according to the method of Hoornaert [*J. Heterocyclic Chem.*, 20, 919, (1983)] to give the pyrazinone. The olefin is oxidatively cleaved with ruthenium tetroxide and the resulting aldehyde is converted to the acid by an oxidizing agent such as chromic acid
- 10 in Step C. The 3-chloro group is then displaced by the appropriate amine, in this case

phenethylamine, in Step D and the remaining chlorine is then removed by reduction with Raney nickel in Step E.




- Amide couplings to form the compounds of this invention can be performed by the carbodiimide method. Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester. Typically, solution phase amide couplings are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead. The addition and removal of one or more protecting groups is also typical practice.

Modifications of the method will allow different W, R³, X and A groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated

synthetic step. For example the starting aldehyde in Step A can have as its side chain, ethyl, isopropyl, cyclopropyl, trifluoromethyl, and the like, to achieve the different operable values of R³. Likewise, different W groups can be present by the use of an appropriate amine in Step D. Different X groups can be present by the omission of
 5 step E, and by the use of a reagent such as oxalyl bromide in step B. Obvious variations and modifications of the method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.

METHOD 5


10 Formation of [RS]-3-benzyl-7-carboxymethyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one (5) is a useful intermediate for preparing compounds of the invention.



It is prepared as follows:

15


Step A: Ethyl 6-methyl-3-nitropyridone 4-carboxylate



To a slurry nitroacetamide ammonia salt (70.3 g, 581 mmol) in 400 mL of deionized water was added 100 g (633 mmol, 1.09 equiv.) of ethyl 2,4-dioxovalerate followed by a solution of piperdinium acetate (prepared by
 20 adding 36 mL of piperdine to 21 mL of acetic acid in 100 mL of water). The resulting solution was stirred at 40°C for 16 h then cooled in an ice bath. The precipitated product was filtered and washed with 50 mL of cold water to afford the above pyridone as a yellow solid.

25 ¹H NMR (CDCl₃) δ 6.43 (s, 1H), 4.35 (q, J=7 Hz, 2H), 2.40 (s, 3H), 1.35 (t, J=7 Hz, 3H).


Step B: Ethyl 2-methoxy-6-methyl-3-nitropyridine 4-carboxylate



A solution of the pyridone from step A (6.2 g, 27.4 mmol) in 50 mL of DCM was treated with 4.47 g (30.2 mmol) of solid trimethyloxonium tetrafluoroborate and the mixture was stirred at 40°C until the reaction was judged to be complete by HPLC (typically 24-72 h). The reaction mixture was concentrated to one-third volume, loaded onto a silica gel column and eluted with 2:3 EtOAc/Hexane to afford the methoxy pyridine as a yellow liquid.

¹H NMR (CDCl₃) δ 7.2 (s, 1H), 4.35 (q, J=7 Hz, 2H), 4.05 (s, 3H), 2.55 (s, 3H), 1.35 (t, J=7 Hz, 3H).


Step C: 4-Hydroxymethyl-2-methoxy-6-methyl-3-nitropyridine



To a -70°C solution of ester from step B (5.4 g, 22.5 mmol) in 140 mL of DCM was added 56.2 mL (56.2 mmol) of DIBAL-H (1M in hexane) by dropping funnel. The resulting solution was stirred for 1h then warmed to room temperature over an additional hour. The reaction mixture was quenched by the careful addition of saturated NaK tartrate. Stirring was continued for 30 min then the solid was filtered and washed with 100 mL of DCM. The filtrate was extracted with 2 x 50 mL of saturated NaK tartrate then brine (25 mL). The yellow solution was concentrated and chromatographed (2:3 EtOAc/Hexane) to afford the desired alcohol as a yellow solid.

¹H NMR (CDCl₃) δ 7.00 (s, 1H), 4.70 (s, 2H), 4.05 (s, 3H), 2.50 (s, 3H), 2.10 (bs, 1H).


Step D: 4-Formyl-2-methoxy-6-methyl-3-nitropyridine



To a -70°C solution of oxalyl chloride (2.0 mL, 22 mmol) in 50 mL of DCM was added 3.4 mL (44 mmol) of DMSO in 10 mL of DCM by dropping funnel. After 2 min, the reaction mixture was treated with 3.99 g (20 mmol) of the alcohol from step C in 20 mL of DCM. The solution was stirred for an additional 15 min at -70°C , treated with 14 mL (50 mmol) of Et_3N and warmed to ambient temperature over 90 min. The reaction was quenched with 100 mL of water and the two phases were separated. The aqueous phase was extracted with 100 mL of DCM and the combined organic extracts were washed with 50 mL of brine and dried over MgSO_4 . The yellow solution was concentrated and chromatographed (2:3 EtOAc/Hexane) to afford the aldehyde as a yellow solid.

$^1\text{H NMR}$ (CDCl_3) δ 10.05 (s, 1H), 7.10 (s, 1H), 4.70 (s, 2H), 4.05 (s, 3H), 2.60 (s, 3H).

Step E: Methyl-2-benzyl-3-(4-[6-methyl-2-methoxy-3-nitropyridyl])-acrylate:




To a 0°C solution of 2-benzyl-trimethylphosphonoacetate (1.36 g, 5.0 mmol) in 25 mL of THF was added 145 mg (4.75 mmol) of NaH. The mixture was stirred for 30 min before the dropwise addition of 930 mg (4.75 mmol) of 4-formyl-2-methoxy-3-nitropyridine in 15 mL of THF. The solution was then heated at 50°C for 3h, cooled and evaporated. The residue was redissolved in 100 mL of EtOAc and quenched to pH=7 with saturated NH_4Cl . The organic phase was washed with brine and dried over MgSO_4 . Column

chromatography (2:3 EtOAc/Hexane) afforded the desired olefin as a mixture of E- and Z-isomers.

^1H NMR (CDCl_3) δ 7.60 (s, 1H), 7.40-7.00 (m, 6H), 6.60 (2 singlets, 2H), 4.00 (2 singlets, 6H), 3.75 (2 singlets, 8H), 2.40 (2 singlets, 6H).

5


Step F: [RS]-3-benzyl-6-methyl-8-methoxy-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridine:



To a solution of nitro olefin from step E (1.6 g, 4.75 mmol) in 50 mL of EtOAc was added 400 mg of 10% Pd(C). Hydrogen gas was added and the solution was heated at 50°C for 16. The reaction mixture was filtered through Celite and the filtrate evaporated. Column chromatography (2:3 EtOAc/Hexane) afforded the bicyclic lactam as a white solid.

^1H NMR (CDCl_3) δ 7.45 (bs, 1H), 7.40-7.20 (m, 5H), 6.45 (s, 1H), 3.95 (s, 3H), 3.35 (dd, 1H), 2.80 (m, 2H), 2.60 (m, 2H), 2.40 (s, 3H).


Step G: [RS]-3-benzyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:



To a 23°C solution of methoxypyridine from step F (700 mg, 2.48 mmol) in 25 mL of dichloroethane was added 8.0 mL (8.0 mmol) of BBr₃ (1M in DCM). An insoluble gum precipitates within 5 min and the reaction was allowed to stir an additional 90 min before quenching to pH = 8 with saturated NaHCO₃. The mixture was diluted with 100 mL of EtOAc and 10 mL THF. The aqueous phase was discarded and the organic solution was washed with 10 mL of water then 10 mL of brine. Evaporation of the solvent left a tan colored solid which was used without further purification.

^1H NMR (CDCl_3) δ 8.20 (bs, 1H), 7.40-7.10 (m, 5H), 5.88 (s, 1H), 3.35 (dd, 1H), 2.80-2.50 (m, 4H), 2.25 (s, 3H).


Step H: [RS]-3-benzyl-7-*t*-butoxycarbonylmethyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:



To a 23°C solution of pyridone from step G (630 mg, 2.5 mmol) in 20 mL of DMF was added 812 mg (2.5 mmol) of Cs_2CO_3 and 0.37 mL (2.5 mmol) of *tert*-butyl bromoacetate. The reaction mixture was allowed to stir for 16 h before removal of the solvent *in vacuo*. The mixture was diluted with 100 mL of EtOAc and 25 mL water. The aqueous phase was discarded and the organic solution was washed with 20 mL of brine. Evaporation of the solvent and chromatography (1:1 EtOAc/Hexane) of the resulting oil left the alkylated pyridone as a white solid.

^1H NMR (CDCl_3) δ 7.84 (bs, 1H), 7.33-7.17 (m, 5H), 5.87 (s, 1H), 4.79 (q, $J=17.2$ Hz, 2H), 3.36 (dd, $J=4.1, 13.5$ Hz, 1H), 2.79 (m, 1H), 2.65 (m, 2H), 2.48 (m, 1H), 2.23 (s, 3H), 1.48 (s, 9H).

Step I: [RS]-3-benzyl-7-carboxymethyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:



To a 0°C solution of ester from step H (310 mg, 0.85 mmol) in 30 mL of DCM was added 8 mL of trifluoroacetic acid. The reaction mixture was allowed to stir to ambient temperature over 5 h before removal of the solvent *in vacuo*. The resulting solid was azeotroped with benzene, EtOAc then ether. This process yielded the desired carboxylic acid as a white solid.

¹H NMR (DMSO-d₆) δ 8.92 (bs, 1H), 7.35-7.10 (m, 5H), 6.04 (s, 1H), 4.75 (q, J=17.2 Hz, 2H), 3.16 (dd, J=4.2, 13.7 Hz, 1H), 2.79 (m, 1H), 2.65-2.40 (m, 3H), 2.1 (s, 3H).

5

EXAMPLE 1

Amides of 5-aminomethyl-7-azaindole were prepared as follows:

Step A: 7-Aza-5-bromoindoline

See Van Der Plas et al., *Tetrahedron* 1989,45, 803, and Taylor et al. *ibid.* 1987, 43, 5145. NBS (2.71 g, 15.2 mmol) was added to a stirred solution of 7-azaindoline (1.83 g, 15.2 mmol, in chloroform (200 mL). After 1 h, the reaction mixture was washed with 10% sodium metabisulfite solution, dried (Na₂SO₄), filtered through a pad of silica (eluting with ethyl acetate) and evaporated *in vacuo* to give the title compound:

¹H NMR (CDCl₃) δ 3.09 (t, J = 8.5 Hz, 2H), 3.74 (t, J = 8.5 Hz, 2H), 5.00 (br s, 1H), 7.32 (s, 1H), 8.13 (s, 1H).

Step B: 7-Aza-5-cyanoindoline

A stirred mixture of 7-aza-5-bromoindole (171 mg, 0.86 mmol), zinc cyanide (61 mg, 0.52 mmol) and tetrakis(triphenylphosphine)palladium(0) (60 mg, 0.052 mmol) in DMF (1 mL) was heated to 80° C under argon. After 5 h, the reaction mixture was partitioned between methylene chloride and water. The organic layer was dried (MgSO₄) and evaporated *in vacuo*. The crude product was purified by flash column chromatography on silica (80% ethyl acetate/hexanes) to give the title compound:

¹H NMR (CDCl₃) δ 3.07 (m, 2H), 3.65 (t, J = 8.4 Hz, 2H), 4.52 (br s, 1H), 7.31 (s, 1H), 7.85 (s, 1H).

Step C: 5-Aminomethyl-7-azaindoline dihydrochloride


A suspension of 7-aza-5-cyanoindoline (98 mg, 0.68 mmol) and 10% palladium on carbon (50 mg) in methanol (10 mL) and 6 M HCl (1 mL) was shaken on a Parr apparatus under hydrogen (55 psi) for 16 h. The mixture was filtered through celite and evaporated *in vacuo* to give the title compound:

^1H NMR (CD_3OD) δ 3.30 (obscured t, 2H), 3.95 (t, $J = 8.2$ Hz, 2H), 4.03 (s, 2H), 7.66 (s, 2H).

5 Step D: 3-(2-Phenethylamino)-6-methyl-1-(5-methylcarbox-amidomethyl-7-azaindolyl)-pyrazinone bis-TFA salt

The title compound was prepared using standard procedures from 3-(2-phenethylamino)-6-methyl-1-carboxymethylpyrazinone and 5-aminomethyl-7-azaindoline dihydrochloride.

10 Step E: 3-(2-Phenethylamino)-6-methyl-1-(5-methylcarbox-amidomethyl-7-azaindolyl)-pyrazinone bis-TFA salt



A mixture of manganese dioxide (9 mg, 0.1 mmol) and 3-(2-phenethylamino)-6-methyl-1-(5-methylcarboxamidomethyl-7-azaindolyl)-pyrazinone bis-TFA salt (12.3 mg, 0.02 mmol) in DMF (1 mL) was stirred for 2 h. Methanol was added and the mixture was filtered through celite and evaporated *in vacuo*. The residue was dissolved in a mixture of methanol and 1 M HCl in ether and was evaporated in *vacuo*. The crude product was purified by preparative HPLC (C_{18} , acetonitrile/water, 0.1% TFA) to give the title compound:

15 ^1H NMR (CD_3OD) δ 2.18 (s, 3H), 3.00 (t, $J = 7.4$ Hz, 2H), 3.67 (t, $J = 7.4$ Hz, 2H), 4.58 (s, 2H), 4.78 (s, 2H), 6.54 (s, 1H), 6.63 (d, $J = 3.7$ Hz, 1H), 7.20-7.7.32 (m, 5H), 7.53 (d, $J = 3.7$ Hz, 1H), 8.25 (s, 1H), 8.27 (s, 1H).

20

EXAMPLE 2

25 Amides of 3-amino-5-aminomethyl-7-azaindazole were prepared as follows:

Step A: 2-amino-3,5-dicyanopyridine

A mixture of 2-amino-6-chloro-3,5-dicyanopyridine (*Synth. Comm.* 1993, 2605, 15.0 g, 84 mmol) and 10% palladium on carbon (10.0 g) in dioxane (150 mL) was shaken on a Parr apparatus under hydrogen (55 psi) for 16 h. More catalyst (7.5 g) was added and after a further 4 h the reaction mixture was

30

filtered through celite washing through with ethanol and evaporated *in vacuo*. The residue was partitioned between methylene chloride and 1 M HCl. The insoluble material was collected by filtration and dried to give the title compound. The methylene chloride layer was washed with brine, dried (Na_2SO_4) and evaporated *in vacuo* to give additional product:

^1H NMR (DMSO) δ 7.93 (br s, 2H), 8.41 (d, $J = 2.2$ Hz, 1H), 8.56 (d, $J = 2.2$ Hz, 1H).

Step B: 2-Chloro-3,5-dicyanopyridine

Acetic acid (37 mL) was added over 10 min to sodium nitrite (13.4 g, 0.194 mol) with stirring. Concentrated sulfuric acid (12.3 mL) was added over 5 min to the resulting thick slurry which was then cooled to 0°C . In a separate flask, pyridinium hydrochloride (14.4 g, 0.125 mol) was added to a stirred mixture of 2-amino-3,5-dicyanopyridine (4.0 g, 27.75 mmol) in acetic acid (55 mL) and the resulting mixture was cooled to 0°C to give a thick slurry. The nitrite slurry was added to the aminopyridine slurry over 5 min with stirring at 0°C . Acetic acid (50 mL) was added and the thick slurry was warmed to rt. After 1 h at rt the mixture was warmed to 50°C and after a further 1 h, it was poured into an ice/water mixture (500 mL). The aqueous mixture was extracted with methylene chloride (4 times) and the combined extracts were dried (Na_2SO_4) and evaporated to a yellow solid. The crude product was purified by chromatography on silica (chloroform/methanol gradient, 1-3% methanol) to give the title compound as a solid:

^1H NMR (CDCl_3) δ 8.34 (d, $J = 2.2$ Hz, 1H), 8.88 (d, $J = 2.2$ Hz, 1H).

Step C: 5-Cyano-3-amino-7-azaindazole

Hydrazine hydrate (55%, 125 μL , 2.20 mmol) was added to a stirred suspension of 2-chloro-3,5-dicyanopyridine (240 mg, 1.47 mmol) and triethylamine (205 μL , 1.47 mmol) in ethanol (3 mL) and the resulting red mixture was heated to 60°C . After 16 h the mixture was cooled and filtered to give the title compound:


^1H NMR (DMSO) δ 5.94 (s, 2H), 8.61 (d, $J = 1.8$ Hz, 1H), 8.66 (d, $J = 1.8$ Hz, 1H), 12.63 (s, 1H).

Step D: 5-Aminomethyl-3-amino-7-azaindazole hydrochloride

The title compound was prepared from 5-cyano-3-amino-7-azaindazole using the procedures of Example 2, Step C, as a red solid:

LRMS = 163.2 (M)⁺.

Step E: 3-(2-Phenethylamino)-6-methyl-1-(5-methylcarbox-amidomethyl-3-amino-7-azaindazolyl)-pyrazinone



5


The title compound was prepared using standard procedures from 3-(2-phenethylamino)-6-methyl-1-carboxymethylpyrazinone and 5-aminomethyl-3-amino-7-azaindazole hydrochloride:

LRMS = 433.2 (M+1).

10

EXAMPLE 3


Preparation of 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethylindazolyl)-pyrazinone



15 The title compound was prepared from 4-bromo-2-fluorobenzonitrile using the procedures of Example 1, Step B followed by Example 2, Steps C-E:
HRMS (FAB) C₂₃H₂₆N₇O₂ (M+1) calcd. 432.2142. Found: 432.2146.

EXAMPLE 4

20 Preparation of 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethyl-7-aza-indazolyl)-pyrazinone bis-TFA salt



Step A: 2-Chloro-6-chloromethyl-3-cyanopyridine

NCS (1.44 g, 10.8 mmol) and benzoyl peroxide (238 mg, 0.98 mmol) were added to a stirred solution of 2-chloro-3-cyano-6-methyl-pyridine (750 mg, 4.92 mmol) in benzene (35 mL) and the mixture was heated to reflux. After 4 h, the mixture was cooled and filtered. The filtrate was diluted with ethyl acetate and
5 was washed with sodium metabisulfite solution, water and brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by chromatography on silica (chloroform) to give the title compound:

¹H NMR (CDCl₃) δ 4.68 (s, 2H), 7.62 (d, J = 7.9 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H).

10 Step B: 6-Azidomethyl-2-chloro-3-cyanopyridine

A mixture of 2-chloro-6-chloromethyl-3-cyanopyridine (600 mg, 3.21 mmol) and sodium azide (229 mg, 3.53 mmol) in DMF (12 mL) were stirred at 50° C for 30 min. The mixture was cooled and partitioned between ethyl acetate and water. The organic layer was washed with water (2 times) and brine, dried
15 (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by chromatography on silica (chloroform) to give the title compound as an oil:

¹H NMR (CDCl₃) δ 4.58 (s, 2H), 7.47 (d, J = 7.9 Hz, 1H), 8.03 (d, J = 7.9 Hz, 1H).

20 Step C: 3-Amino-6-azidomethyl-7-azaindazole

The title compound was prepared from 6-azidomethyl-2-chloro-3-cyanopyridine using the procedures of Example 2, Step C, as a tan solid:
¹H NMR (DMSO) δ 4.52 (s, 2H), 5.56 (s, 2H), 6.98 (d, J = 8.1 Hz, 1H), 8.12 (d, J = 8.1 Hz, 1H), 11.97 (s, 1H).

25 Step D: 3-Amino-6-aminomethyl-7-azaindazole

A mixture of 3-amino-6-azidomethyl-7-azaindazole (60 mg, 0.317 mmol), triphenylphosphine (416 mg, 1.59 mmol) and water (86 mg, 4.76 mmol) in THF (10 mL) was stirred for 64 h. The solvent was evaporated *in vacuo* and the residue was purified by chromatography on silica (chloroform/ammonia, methanol
30 gradient, 5-10% methanol) to give the title compound as a yellow solid:

¹H NMR (CDCl₃ + CD₃OD) δ 4.03 (s, 2H), 6.98 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H).

35 Step E: 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethyl-7-aza-indazolyl)-pyrazinone bis-TFA salt


The title compound was prepared using standard procedures from 3-(2-phenethylamino)-6-methyl-1-carboxymethylpyrazinone and 3-amino-6-aminomethyl-7-azaindazole.

HRMS (FAB) $C_{22}H_{25}N_8O_2$ (M+1) calcd. 433.2095. Found: 433.2112.

5

EXAMPLE 5

Preparation of 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethyl-1,2-benzisoxazolyl)-pyrazinone:



10 Step A: O-(2,5-Dicyanophenyl)-acetophenone oxime

Acetophenone oxime (0.58 g, 4.29 mmol) was added to a stirred 1M potassium t-butoxide in THF (4.49 mL). After 30 min a solution of 2,5-dicyanofluorobenzene (0.57 g, 3.90 mmol) in THF (10 mL) was added over 5 min. After 16 h the reaction was quenched with saturated ammonium chloride solution (5 mL) and the volatiles were evaporated *in vacuo*. The residue was partitioned between ethyl acetate and brine and the organic layer was dried (Na_2SO_4) and evaporated *in vacuo* to give the title compound as a solid:

15

1H NMR ($CDCl_3$) δ 2.57 (s, 3H), 7.36 (dd, $J = 1.1$ and 8.0 Hz, 1H), 7.49 (m, 3H), 7.69 (d, $J = 8.0$ Hz, 1H), 7.77 (dd, $J = 2.2$ and 8.0 Hz, 2H), 8.00 (d, $J = 1.1$ Hz, 1H).

20

Step B: 3-Amino-6-cyano-1,2-benzisoxazole

A stirred mixture of O-(2,5-dicyanophenyl)-acetophenone oxime (0.92 g, 3.5 mmol) in ethanol (10 mL) and 3 M HCl (10 mL) was heated to reflux for 3 h. The mixture was cooled and concentrated *in vacuo*. The residual aqueous mixture was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic layer was washed with brine, dried (Na_2SO_4) and evaporated *in vacuo* to give the title compound as a yellow solid:

25

Step C: 3-Amino-6-aminomethyl-1,2-benzisoxazole

Borane methylsulfide complex (2 M in THF, 1.98 mL) was added to a stirred refluxing solution of 3-amino-6-cyano-1,2-benzisoxazole (210 mg,

30

1.32 mmol) in DME (10 mL). After 45 min excess methyl sulfide was evaporated and the reaction mixture was cooled and quenched with 1M HCl solution (10 mL). The mixture was stirred for 30 min and then was neutralised with sodium bicarbonate solution and concentrated to dryness. The residue was triturated with 5%

methanol/chloroform, filtered and the filtrate evaporated in vacuo. The residue was purified by chromatography on silica (5% methanol, chloroform/ammonia) to give the title compound as a yellow solid:

¹H NMR (CDCl₃ + CD₃OD) δ 4.80 (s, 2H), 7.20 (dd, J = 1.1 and 8.1 Hz, 1H), 7.37 (s, 1H), 7.53 (d, J = 8.1 Hz, 1H).


Step D: 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methyl-carboxamidomethyl-1,2-benzisoxazolyl)-pyrazinone

The title compound was prepared using standard procedures from 3-(2-phenethylamino)-6-methyl-1-carboxymethylpyrazinone and 3-amino-6-aminomethylbenzisoxazole.

LRMS (FAB) C₂₃H₂₅N₆O₃ 433.3 (M+1).

EXAMPLE 6

Preparation of 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethylindazolyl)-pyrazinone bis-TFA salt



Step A: 6-Cyanoindazole

A solution of sodium nitrite (218 mg, 3.16 mmol) in water (1 mL) was added dropwise over 2 min to a stirred suspension of 3-amino-6-cyanoindazole (250 mg, 1.58 mmol) in water (1 mL) and acetic acid (2 mL) at 0° C. The resulting thick suspension was warmed to rt. After 16 h the mixture was cooled to 0° C and the solids were collected by filtration, washing with cold water. The solids were suspended in 0.1 M HCl (4 mL), DME (3 mL) was added and the resulting mixture was stirred and heated to 80° C for 1.5 h. The reaction was cooled and concentrated to 1/3 the volume. The residue was neutralised with sodium bicarbonate and extracted with ethyl acetate. The ethyl acetate layer was washed with water and brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by

chromatography on silica (5:1 chloroform/ethyl acetate) to give the title compound as a yellow solid:

LRMS = 143.1 (M)⁺; ¹H NMR (CDCl₃) δ 7.39 (dd, J = 1.1 and 8.3 Hz, 1H), 7.87 (dd, J = 0.9 and 8.3 Hz, 1H), 7.94 (dd, J = 0.9 and 2.1 Hz, 1H), 8.21 (d, J = 0.9 Hz, 1H).

5

Step B: 6-Aminomethylindazole dihydrochloride

The title compound was prepared using the procedures of Example 2, Step C, as a solid:

¹H NMR (CD₃OD) δ 4.26 (s, 2H), 7.23 (d, J = 8.4 Hz, 1H), 7.67 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 0.9 Hz, 1H).

10

Step D: 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methyl-carboxamidomethylindazolyl)-pyrazinone bis-TFA salt

The title compound was prepared using standard procedures from 3-(2-phenethylamino)-6-methyl-1-carboxymethylpyrazinone and 3-amino-6-aminomethylindazole dihydrochloride.

15

HRMS (FAB) C₂₃H₂₅N₆O₂ (M+1) calcd. 417.2033. Found: 417.2038.

EXAMPLE 7

Amides of 5-aminomethylindazole were prepared as follows:

20

Step A: 5-Cyano-2-fluorobenzaldehyde

To a solution of 5-bromo-2-fluorobenzaldehyde (1.93 g, 9.51 mmol) in DMF (4 mL) was added copper(I) cyanide (0.98 g, 10.93 mmol). The mixture was heated to 190 °C and stirred for 5h. The dark brown reaction mixture was poured into a solution containing ferric chloride (3.0 g), conc. HCl (0.93 mL) and water (6 mL) and warmed to 65 °C for 20 min. The mixture was partitioned between toluene (20 mL) and water (20 mL). The organic was washed with diluted HCl (25 mL), water (20 mL), 10% sodium hydroxide (25 mL), dried over magnesium sulfate, and concentrated to provide a solid product:

25

30

¹H NMR (CDCl₃) δ 10.34 (m, 1H), 8.21 (m, 1H), 7.90 (m, 1H), 7.35 (m, 1H).

Step B: 5-Cyanoindazole

5-Cyano-2-fluorobenzaldehyde (512 mg, 3.43 mmol) was dissolved in hydrazine hydrate (25 mL) at room temperature and the solution left to

35

stand overnight. To this reaction mixture was added methylene chloride (30 mL). The mixture was purified by filtration through a pad of silica eluting with methylene chloride, concentrated *in vacuo* to afford a white solid:

^1H NMR (DMSO) δ 8.40 (s, 1H), 8.25 (s, 1H), 7.69 (m, 2H).

5

Step C: 5-Aminomethylindazole

To a solution of LiAlH_4 (0.76 g, 20.1 mmol) in THF (10 mL) cooled to 0°C was added a solution of 5-cyanoindazole (0.64 g, 4.47 mmol) in THF (10 mL) dropwise. After 0.5 h the reaction mixture was warmed to reflux for 2 h, then cooled to 0°C and quenched by the careful addition of water (0.76 mL), 1.0 N sodium hydroxide (0.76 mL), and water (2.28 mL). This mixture was filtered through a pad of celite and washed with THF/MeOH (3:1, 300 mL). Removal of the solvent *in vacuo* provided a solid which was purified via flash column chromatography (25 x 150 mm column; elution with MeOH : CH_2Cl_2 : CH_2Cl_2 saturated with NH_3 , 10 : 60 : 30). This afforded the title compound as a light yellow solid:


^1H NMR (CDCl_3) δ 10.0 (s, 1H), 8.61 (s, 1H), 8.15 (s, 1H), 7.90-7.60 (m, 2H), 4.92 (s, 2H).

10

15

Step D: 3-(2-Phenylethylamino)-6-methyl-1-(5-methylene-carboxamidomethylindazolyl)-pyrazinone

20



The title compound was prepared from 5-aminomethylindazole using standard procedures:

HRMS (FAB-POS $\text{M}+1$): calcd 417.2033 found 417.2043

25 Analysis: calculated for $\text{C}_{23}\text{H}_{24}\text{N}_6\text{O}_2$ 0.1 TFA

C65.12 H5.68 N19.64

Found: C65.49 H5.62 N19.28

EXAMPLE 8


30 Amides of 5-aminomethyl-1-methylindazole were prepared as follows:

Step A: 5-Cyano-1-methylindazole

To a solution of 5-cyano-2-fluorobenzaldehyde (0.50 g, 3.35 mmol) in ether (5 mL) was added methyl hydrazine (0.178 μ L, 3.35 mmol) dropwise at room temperature. The mixture was stirred at room temperature for 1 h and concentrated *in vacuo* to give the hydrazone as a yellow solid. This solid was fused at 230 $^{\circ}$ C for 10 min, cooled to rt, dissolved in CH_2Cl_2 and purified by filtration through a pad of silica (eluant CH_2Cl_2 : MeOH; 19 : 1) to afford the title compound as a light yellow solid: ^1H NMR (DMSO) δ 8.38 (s, 1H), 8.23 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 4.09 (s, 3H).

Step B: 5-Aminomethyl-1-methylindazole

The title compound was prepared according to the method described in Example 7, Step C, 5-cyano-1-methylindazole as a starting material: ^1H NMR (CDCl_3) δ 7.93 (s, 1H), 7.63 (s, 1H), 7.36 (s, 2H), 4.72 (s, 3H), 4.07 (s, 2H); CI-MS: m/e = 162.10 (M+1).

Step C: 3-(2-Phenylethylamino)-6-methyl-1-(1-methyl-5-methylenecarboxamidomethylindazolyl)-pyrazinone

The title compound was prepared from 5-aminomethyl-1-methylindazole using standard procedures:

HRMS (FAB-POS M+1): calcd 431.2190 found 431.2179

Analysis: calculated for $\text{C}_{24}\text{H}_{26}\text{N}_6\text{O}_2$ 0.30 H_2O

C66.12 H6.15 N19.28

Found: C66.07 H5.91 N18.95

EXAMPLE 9

Amides of 6-aminomethyl-1-methylindazole were prepared as follows:

Step A: 4-cyano-2-fluorobenzaldehyde

The title compound was prepared according to the method described in Example 7, Step A, 4-bromo-2-fluorobenzaldehyde as a starting material: ^1H NMR (DMSO) δ 10.23 (s, 1H), 8.10-7.86 (m, 3H).

5 Step B: 6-Cyano-1-methylindazole

The title compound was prepared according to the method described in Example 8, Step A, 4-cyano-2-fluorobenzaldehyde and methyl hydrazine as starting materials: ^1H NMR (CDCl_3) δ 8.07 (s, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.79 (s, 1H), 7.37 (d, J = 8.3 Hz, 1H), 4.14 (s, 3H).


10

Step C: N-methyl-6-aminomethylindazole

The title compound was prepared according to the method described in Example 7, Step C, 6-cyano-1-methylindazole as a starting material: ^1H NMR (CDCl_3) δ 7.94 (s, 1H), 7.68 (d, J = 7.3 Hz, 1H), 7.37 (s, 1H), 7.09 (d, J = 7.2

15

Step D: 3-[2-(2-pyridyl)ethylamino]-6-methyl-1-(1-methyl-6-methylenecarboxamidomethylindazolyl)-pyrazinone



20 The title compound was prepared from 6-aminomethyl-1-methylindazole using standard procedures:

HRMS (FAB-POS M+1): calcd 432.2164 found 432.2142


Analysis: calculated for $\text{C}_{23}\text{H}_{25}\text{N}_7\text{O}_2$ 0.50 HOAc

 C62.45 H5.90 N21.25

25 Found: C62.74 H5.65 N20.93

EXAMPLE 10

Preparation of 3-[2-(3,4-methylenedioxyphenyl)ethylamino]-6-methyl-1-(1-methyl-6-methylenecarboxamidomethylindazolyl)-pyrazinone



The title compound was prepared from 6-aminomethyl-1-methylindazole using standard procedures:

HRMS (FAB-POS M+1): calcd 475.2088 found 475.2102


5 Analysis: calculated for $C_{25}H_{26}N_6O_4 \cdot 0.15 CHCl_3$

C62.62 H5.99 N16.08

Found: C62.84 H5.61 N15.88

EXAMPLE 11

10 Preparation of 3-(2-Phenethylamino)-6-methyl-1-(6-methylcarboxamidomethylindolyl)-pyrazinone



The title compound was prepared from 6-aminomethylindole using standard procedures:

15 HRMS (FAB) $C_{24}H_{26}N_5O_2$ (M+1) calcd. 416.2081. Found: 416.2094.

EXAMPLE 12

Tablet Preparation

Tablets containing 25.0, 50.0, and 100.0 mg., respectively, of the following active compounds are prepared as illustrated below (compositions A-D).

20 Active I is 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethylindazolyl)-pyrazinone; Active II is 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethyl-7-aza-indazolyl)-pyrazinone bis-TFA salt; Active III is 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-

25 methylcarboxamidomethyl-1,2-benzisoxazolyl)-pyrazinone; and Active IV is 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethylindazolyl)-pyrazinone bis-TFA salt.

Amount-mg

<u>Component</u>	<u>A</u>	<u>B</u>	<u>C</u>	<u>D</u>	<u>E</u>	<u>F</u>	<u>G</u>	<u>H</u>	<u>I</u>
Active I	25	50	100	-	-	-	-	-	-
Active II	-	-	-	25	50	100	-	-	-
Active III	-	-	-	-	-	-	25	50	100
Micro-crystalline cellulose	37.25	100	200	37.25	100	200	37.25	100	200
Modified food corn starch	37.25	4.25	8.5	37.25	4.25	8.5	37.25	4.25	8.5
Magnesium stearate	0.5	0.75	1.5	0.5	0.75	1.5	0.5	0.75	1.5

All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.

25

EXAMPLE 13Tablet Preparation

Exemplary compositions of 3-(2-Phenethylamino)-6-methyl-1-(3-amino-6-methylcarboxamidomethylindazolyl)-pyrazinone bis-TFA salt tablets are shown below:

30

Component	0.25 mg	2 mg	10 mg	50 mg
Active IV	0.500%	1.000%	5.000%	14.29%
mannitol	49.50%	49.25%	47.25%	42.61%
microcrystalline cellulose	49.50%	49.25%	47.25%	42.61%

magnesium stearate	0.500%	0.500%	0.500%	0.500%
--------------------	--------	--------	--------	--------

2, 10 and 50 mg tablets were film-coated with an aqueous dispersion of hydroxypropyl cellulose, hydroxypropyl methylcellulose and titanium dioxide, providing a nominal weight gain of 2.4%.

5

Tablet preparation via direct compression

Active IV, mannitol and microcrystalline cellulose were sieved through mesh screens of specified size (generally 250 to 750 μ m) and combined in a suitable blender. The mixture was subsequently blended (typically 15 to 30 min) until the drug was uniformly distributed in the resulting dry powder blend. Magnesium stearate was screened and added to the blender, after which a precompression tablet blend was achieved upon additional mixing (typically 2 to 10 min). The precompression tablet blend was then compacted under an applied force, typically ranging from 0.5 to 2.5 metric tons, sufficient to yield tablets of suitable physical strength with acceptable disintegration times (specifications will vary with the size and potency of the compressed tablet). In the case of the 2, 10 and 50 mg potencies, the tablets were dedusted and film-coated with an aqueous dispersion of water-soluble polymers and pigment.

20 Tablet preparation via dry granulation

Alternatively, a dry powder blend is compacted under modest forces and remilled to afford granules of specified particle size. The granules are then mixed with magnesium stearate and tableted as stated above.

25

EXAMPLE 14

Intravenous Formulations

Intravenous formulations of were prepared according to general intravenous formulation procedures.

30

<u>Component</u>	<u>Estimated range</u>
Active IV	0.12 - 0.61 mg
D-glucuronic acid*	0.5 - 5 mg
Mannitol NF	50-53 mg

Water for injection q.s. 1.0 mL

1N sodium hydroxide is used to achieve a solution pH in the range of between 3.9-4.1.

5

Exemplary compositions A-C are as follows:


	<u>Component</u>	<u>A</u> <u>B</u> <u>C</u>		
	Active IV	0.61 mg*	0.30**	0.15***
10	D-glucuronic acid*	1.94 mg	1.94 mg	1.94 mg
	Mannitol NF	51.2 mg	51.2 mg	51.2 mg
	1 N Sodium Hydroxide	q.s. pH 4.0	q.s. pH 4.0	q.s. pH 4.0
	Water for injection	q.s. 1.0 mL	q.s. 1.0 mL	q.s. 1.0 mL

15 * 0.50 mg free base; ** 0.25 mg free base; *** 0.12 mg free base

Various other buffer acids, such as L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration may be substituted for glucuronic acid.

WHAT IS CLAIMED IS:



1. A compound having the formula:



- 5 or a pharmaceutically acceptable salt thereof, wherein b is NY^1 or O; c is CY^2 or N; d is CY^3 ; e is CY^4 or N; f is CY^5 or N; g is CY^6 or N; Y^4 , Y^5 , and Y^6 are independently hydrogen, C_{1-4} alkyl, or halogen; Y^1 , and Y^2 are independently hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, halogen, NH_2 , OH or C_{1-4} alkoxy, and Y^3 is hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, halogen, NH_2 , OH, CN or C_{1-4} alkoxy;

10

A is




W is

- 15 hydrogen,
 R^1 ,
 R^1OCO ,
 R^1CO ,
 R^1SO_2 ,
20 $R^1(CH_2)_nNHCO$, or
 $(R^1)_2CH(CH_2)_nNHCO$,

wherein n is 0-4;

R¹ is

- 5 R²,
 R²(CH₂)_mC(R⁸)₂, where m is 0-3, and each R⁸ can be the same or different,
 (R²)(OR²)CH(CH₂)_p, where p is 1-4,



- 10 R²C(R⁸)₂(CH₂)_m, wherein m is 0-3, and each R⁸ can be the same or
 different, wherein (R⁸)₂ can also form a ring with C represented by
 C₃₋₇ cycloalkyl,
 R²CH₂C(R⁸)₂(CH₂)_q, wherein q is 0-2, and each R⁸ can be the same or
 different, wherein (R⁸)₂ can also form a ring with C represented by
 C₃₋₇ cycloalkyl,
 15 (R²)₂CH(CH₂)_r, where r is 0-4 and each R² can be the same or different, and
 wherein (R²)₂ can also form a ring with CH represented by C₃₋₇
 cycloalkyl, C₇₋₁₂ bicyclic alkyl, C₁₀₋₁₆ tricyclic alkyl, or a 5- to 7-
 membered mono- or bicyclic heterocyclic ring which can be saturated
 or unsaturated, and which contains from one to three heteroatoms
 20 selected from the group consisting of N, O and S,
 R²O(CH₂)_p, wherein p is 1-4,
 R²CF₂C(R⁸)₂,
 (R²CH₂)(R²CH₂)CH, or
 R²SO₂,
 25 R²CH₂SO₂,
 R²(COOR⁶)(CH₂)_r, where r is 1-4;

- R² and R⁵ are independently
 hydrogen,
 30 phenyl, unsubstituted or substituted with one or more of C₁₋₄

- alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂, CH₂OH,
CO₂R⁷, where R⁷ is C₁₋₄ alkyl, or SO₂NH₂,
naphthyl,
biphenyl,
5 a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring or non-heterocyclic ring which can be saturated or
unsaturated, wherein the heterocyclic ring contains from one to four
heteroatoms selected from the group consisting of N, O and S, and wherein
the heterocyclic or non-heterocyclic ring is unsubstituted or substituted with
10 halogen or hydroxy,
C₁₋₇ alkyl, unsubstituted or substituted with one or more of hydroxy,
COOH,
amino,
aryl,
15 C₃₋₇ cycloalkyl,
CF₃,
N(CH₃)₂,
-C₁₋₃alkylaryl,
heteroaryl, or
20 heterocycloalkyl,
CF₃
C₃₋₇ cycloalkyl, unsubstituted or substituted with aryl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl;
25 R³, R⁴ and R⁶ are independently selected from the group consisting of
hydrogen,
halogen,
C₁₋₄ alkyl,
30 C₃₋₇ cycloalkyl,
trifluoromethyl,
CN,
SCH₃,
SOCH₃, or

SO₂CH₃;

X is

5 hydrogen, or
halogen;


Z is CH₂, S, or SO₂;

R⁸ is

10 hydrogen,
phenyl, unsubstituted or substituted with one or more of C₁₋₄
alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂,
halogen,
naphthyl,
15 biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring which can be saturated or unsaturated, and which contains
from one to four heteroatoms selected from the group consisting of N, O and
S,
20 C₁₋₄ alkyl, unsubstituted or substituted with one or more of hydroxy,
COOH,
amino,
aryl,
heteroaryl, or
25 heterocycloalkyl,
CF₃
C₃₋₇ cycloalkyl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl,

30



2. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, includes those wherein A is



wherein R^3 is CH_3 or Cl .





3. A compound of Claim 2, or a pharmaceutically acceptable salt thereof, includes those wherein
- 5 Y^1, Y^2, Y^3, Y^4, Y^5 , and Y^6 are independently hydrogen, C_{1-4} alkyl, or NH_2 ; W is R^1 ; R^1 is $R^2(CH_2)_2-$; and R^2 is a 5- to 7-membered mono- or a 9- to 10-membered bicyclic heterocyclic ring or non-heterocyclic ring which can be saturated or unsaturated, wherein the heterocyclic ring contains from one to four heteroatoms selected from the group consisting of N, O, and S, and wherein the heterocyclic ring is unsubstituted.
- 10


4. A compound of Claim 3, or a pharmaceutically acceptable salt thereof, Y^1, Y^2, Y^3, Y^4, Y^5 , and Y^6 are independently hydrogen, methyl or NH_2 ;
- 15 and W is



5. A compound of Claim 4, or a pharmaceutically acceptable salt thereof, wherein b is NH , $N(CH_3)$ or O , c is CH or N , d is CH , $C(NH_2)$, e is CH , f is
- 20 N or CH , and g is CH or N .

6. A compound of Claim 5, or a pharmaceutically acceptable salt thereof, selected from the group consisting of





7. A pharmaceutical composition comprising a therapeutically
5 effective amount of a compound of Claim 1.

8. A method for inhibiting thrombus formation in blood
comprising adding to the blood a composition of Claim 7.

9. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombin, inhibiting thrombus formation, treating thrombus formation, or preventing thrombus formation in a mammal.

5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25041

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07D 403/12, 401/12; A61K 31/435, 31/495

US CL : 546/119, 123, 296, 297 ; 544/405; 514/303, 300, 252, 255

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U S : 546/119, 123, 296, 297 ; 544/405; 514/303, 300, 252, 255

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database CA on STN. Chem. abs. Vol. 129, 1998, (Columbus, OH, USA), abstract No. 302552, KITAZAWA et al. "Preparation of 1,4-disubstituted cyclic amine derivatives as serotonin antagonists," WO 98/43956, see entire abstract.	1-7
A,E	US 5,981,546 A (DUGGAN et al.) 09, November 1999, col. 9, lines 15-25, col. 11, lines 15-25, 40.	1-7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 JANUARY 2000

Date of mailing of the international search report

11 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JANE FAN

Telephone No. (703) 308-0198

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/25041

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
2-6 and 1, 7-9 (A is the first three formulas in claim 1)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☒

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/25041

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1, 7-9 (in part), drawn to pyridones wherein A is the first and third structure in claim 1.

Group II, claim(s) 2-6 and claims 1, 7-9 (in part), drawn to pyrazinones wherein A is the second structure in claim 1.

Group III, claim(s) 1, 7-9 (in part), drawn to 1,2,3,4 tetrahydro-1,7 naphthridine [7H]-8-ones wherein A is the fourth structure in claim 1.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: compounds encompassing pyridones and pyrazinones have other use such as being integrin antagonists. Note pat' 5,981,546 by Duggan et al. Furthermore, compounds containing indolyl methyl amino carbonyl methyl moiety have other use such as central muscle relaxant. Note CA 129:302552